BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33120166)

  • 1. CTNNB1 p.L31P mutation in an ovarian endometrioid carcinoma with synchronous uterine endometrioid carcinoma.
    Pecorella I; Coppa A; Nicolussi A; Manganaro L; Fiorentin F; Palaia I; Muzii L
    Pathol Res Pract; 2020 Dec; 216(12):153260. PubMed ID: 33120166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis.
    Irving JA; Catasús L; Gallardo A; Bussaglia E; Romero M; Matias-Guiu X; Prat J
    Hum Pathol; 2005 Jun; 36(6):605-19. PubMed ID: 16021566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
    Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
    Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
    McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas.
    Catasús L; Bussaglia E; Rodrguez I; Gallardo A; Pons C; Irving JA; Prat J
    Hum Pathol; 2004 Nov; 35(11):1360-8. PubMed ID: 15668893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synchronous ovarian endometrioid adenocarcinoma with a functioning stroma and endometrial endometrioid adenocarcinoma by different loss of heterozygosity findings.
    Takai N; Kai K; Tsuno A; Nasu K; Kashima K; Narahara H
    Arch Gynecol Obstet; 2011 Oct; 284(4):951-5. PubMed ID: 21046134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
    Lin WM; Forgacs E; Warshal DP; Yeh IT; Martin JS; Ashfaq R; Muller CY
    Clin Cancer Res; 1998 Nov; 4(11):2577-83. PubMed ID: 9829719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
    Valtcheva N; Lang FM; Noske A; Samartzis EP; Schmidt AM; Bellini E; Fink D; Moch H; Rechsteiner M; Dedes KJ; Wild PJ
    BMC Cancer; 2017 Jan; 17(1):66. PubMed ID: 28103826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular evidence for a clonal relationship between synchronous uterine endometrioid carcinoma and ovarian clear cell carcinoma: a new example of "precursor escape"?
    Weng CH; Wu RC; Chen SJ; Chen HC; Tan KT; Lee YS; Huang SS; Yang LY; Wang CJ; Chou HH; Chao AS; Chao A; Lai CH
    J Mol Med (Berl); 2021 Jul; 99(7):959-966. PubMed ID: 33768299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology.
    Chao A; Wu RC; Jung SM; Lee YS; Chen SJ; Lu YL; Tsai CL; Lin CY; Tang YH; Chen MY; Huang HJ; Chou HH; Huang KG; Chang TC; Wang TH; Lai CH
    Gynecol Oncol; 2016 Oct; 143(1):60-67. PubMed ID: 27498588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synchronous Endometrial and Ovarian Carcinomas: Pathologic and Molecular Analysis Highlights the Monoclonal Origin of the Lesions.
    Guerriero A; Moro M; Angerilli V; Munari G; Santoro L; Alessandrini L; Favero L; Tasca G; Fassan M; Dei Tos AP
    Int J Gynecol Pathol; 2024 Jul; 43(4):309-315. PubMed ID: 37922918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
    Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.
    Schultheis AM; Ng CK; De Filippo MR; Piscuoglio S; Macedo GS; Gatius S; Perez Mies B; Soslow RA; Lim RS; Viale A; Huberman KH; Palacios JC; Reis-Filho JS; Matias-Guiu X; Weigelt B
    J Natl Cancer Inst; 2016 Jun; 108(6):djv427. PubMed ID: 26832770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
    Ma SK; Zhang HT; Sun YC; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biological analysis revealed a case of synchronous endometrial and ovarian cancer with different histological grade as metastatic ovarian cancer from endometrial cancer: Case report and review of literature.
    Yumisashi R; Saito R; Togami S; Kobayashi Y; Kitazono I; Tanimoto A; Kobayashi H
    J Obstet Gynaecol Res; 2023 Nov; 49(11):2766-2770. PubMed ID: 37604499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
    Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
    Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and pathologic data to guide selection of patients with endometrioid endometrial cancer for ovarian preservation.
    Manning-Geist BL; Rios-Doria E; Liu YL; Ellenson LH; Zhou QC; Iasonos A; Leitao MM; Abu-Rustum NR; Weigelt B; Mueller JJ
    Int J Gynecol Cancer; 2024 May; 34(5):697-704. PubMed ID: 38508587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
    Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
    Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.